31.7 C
New York
Sunday, June 14, 2026

Tag: press release

newssourceFORcompanyinformationcontent1marketreleases

Terra Property Trust, Inc. Announces Extension of Expiration Date of Registered Exchange Offer

NEW YORK, June 11, 2026 (GLOBE NEWSWIRE) -- Terra Property Trust, Inc. (the “Company”) announced yesterday that it has extended the expiration date of its previously announced exchange offer (the “Exchange Offer”) to exchange all validly tendered unsecured 6.00% Senior Notes due June 30, 2026, issued by the Company (the “Existing Notes”) for a combination of (i) new 11.00% Senior Secured Notes due July 1, 2027 to be issued by the Company (the “Exchange Notes”) and (ii) cash. The Exchange Offer is being made pursuant to the Company’s Registration Statement on Form S-4 (File No. 333-295631) (as amended, the “Registration Statement”), which has been filed with the Securities and Exchange Commission (the “SEC”).

Share Buyback Transaction Details June 4 – June 10, 2026

PRESS RELEASE                                        

Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026

ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced an upcoming presentation at Clinical Trials at the Summit 2026, taking place on June 12-13, 2026, in Las Vegas, Nevada.

Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026

ZUG, Switzerland, June 11, 2026 – Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced an upcoming presentation at Clinical Trials at the Summit 2026, taking place on June 12-13, 2026, in Las Vegas, Nevada.

Zoetis Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – ZTS

LOS ANGELES, June 11, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Zoetis Inc. ("Zoetis" or "the...

Crédit Agricole Financement de l’Habitat SFH : EARLY REPURCHASE OF ISIN FR001400JM17

Montrouge, June 11, 2026

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven...

Patients in the IMAAVY 30 mg/kg treatment groupa achieved statistically significant durable hemoglobin responseb, with mean hemoglobin improvement of at least 1 g/dL as...

Vivoryon Therapeutics N.V. Reports Q1 2026 Financial Results and Provides Business Update

Vivoryon Therapeutics N.V. Reports Q1 2026 Financial Results
and Provides Business Update

HORIZON PETROLEUM COMMENCES CIVIL WORKS AT THE LACHOWICE 7 WELLSITE IN POLAND

CALGARY, AB, June 10, 2026 /PRNewswire/ - Horizon Petroleum Ltd. ("Horizon" or the "Company") (TSXV: HPL) (FRA: HPM) (Tradegate: HPM) is pleased to announce the...

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the pricing of an underwritten public offering of 47,619,048 shares of its common stock at a public offering price of $1.05 per share. The aggregate gross proceeds from this offering are expected to be $50 million, before deducting underwriting discounts and commissions and other offering expenses payable by Humacyte. The closing of the offering is expected to occur on or about June 12, 2026, subject to the satisfaction of customary closing conditions. In addition, Humacyte has granted the underwriters an option for a period of 30 days to purchase up to an additional 7,142,857 shares of Humacyte’s common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being sold by Humacyte.

Greenberg Traurig Advises Kayne Anderson-BKM Joint Venture on $1.81B Light Industrial Portfolio Acquisition

NEW YORK, June 10, 2026 /PRNewswire/ -- Attorneys at global law firm Greenberg Traurig, LLP represented Kayne Anderson Real Estate (Kayne Anderson) and BKM...

Five Star Bancorp Names Cliff Cooper as Executive Vice President / Food, Agribusiness & Diversified Industries President

Industry veteran to continue bringing high-touch, relationship-driven financial services to agriculture, food production, and related industries 
Industry veteran to continue bringing high-touch, relationship-driven financial services to agriculture, food production, and related industries

Replenish Nutrients to Present at the Planet MicroCap Las Vegas Powered by MicroCapClub

OKOTOKS, AB, June 10, 2026 /CNW/ - Replenish Nutrients Holding Corp. (CSE: ERTH) (OTC: VVIVF) ("Replenish" or the "Company"), is pleased to announce that it...

SafeSpace Global Announces Launch of New Addiction Treatment Vertical, Supported by Signed Master Services Agreement and Conditional $2 Million Funding Commitment

KNOXVILLE, TN, June 10, 2026 (GLOBE NEWSWIRE) -- SafeSpace Global Corporation (“SafeSpace Global” or the “Company”), a provider of AI-powered physical safety and security solutions for regulated care environments, today announced the launch of its new Addiction Treatment Vertical, supported by a newly executed Master Services Agreement (“MSA”) with Antidote Health Ventures and a conditional funding commitment from Method Five Labs, LLC (“Method Five Labs”).

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPress release

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers